并发症对不同临时机械循环支持技术生存结局的影响
该单中心回顾性研究纳入493例心源性休克患者,分析静脉-动脉体外生命支持、微轴流泵及两者联合(ECMELLA)治疗中并发症对死亡率的累积影响,并按非心脏外科与心脏外科患者分层。结果显示并发症常见且与死亡率升高明显相关,出血、需肾脏替代治疗和严重溶血最常见。
要点
- 非心脏外科患者发生1个并发症死亡HR为1.92,≥2个为3.73。
- 心脏外科患者发生1个并发症死亡HR为2.22,≥2个为3.44。
- 出血、需肾脏替代治疗和严重溶血为最常见并发症。
核心结论
- 接受临时机械循环支持治疗的患者并发症常见,且与死亡风险升高明显相关。
研究设计与样本
- 单中心回顾性分析,纳入493例因各种原因心源性休克接受静脉-动脉体外生命支持、微轴流泵或两者联合(ECMELLA)治疗的患者,总支持天数4881天。
主要发现
- 非心脏外科患者中,与无并发症者相比,1个并发症死亡HR为1.92(95%CI 1.22–3.00,p=0.004),≥2个并发症HR为3.73(95%CI 2.48–5.60,p<0.001)。
- 心脏外科患者中,1个并发症死亡HR为2.22(95%CI 1.29–3.81,p=0.004),≥2个并发症HR为3.44(95%CI 2.04–5.78,p<0.001)。
- 非心脏外科与心脏外科患者中最常见并发症分别为出血(33%与60%)、需肾脏替代治疗(31%与43%)和严重溶血(26%与35%)。
临床怎么用
- 对接受临时机械循环支持的心源性休克患者应重视并发症的累积效应,尤其出血、肾功能替代需求和溶血,以协助风险分层与密切监测。
局限性
- 原文未明确报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Temporary mechanical circulatory support (tMCS) has become a standard treatment in cardiogenic shock but is associated with high complication rates. This study analyzes common complications associated with modern tMCS devices and their impact on mortality depending on the tMCS approach. METHODS: We conducted a retrospective single-center analysis of patients with all-cause cardiogenic shock treated with veno-arterial extracorporeal life support, microaxial flow pump, and a combination of both (ECMELLA). The primary outcome was the impact of cumulative complications on mortality, evaluated separately for nonsurgical (non-PCCS) and cardiac surgical (PCCS) patients. Secondary outcomes included the impact of complications on mortality stratified by tMCS type and rates of bleeding, the need for renal replacement therapy (RRT), hemolysis, neurological complications, bloodstream infections, and ischemic limb complications. RESULTS: We included 493 patients, totaling 4,881 days on tMCS support. Non-PCCS patients with 1 complication had a hazard ratio (HR) of 1.92 (95% confidence interval [CI]: 1.22, 3.00, p = 0.004) for mortality and 3.73 (95% CI: 2.48, 5.60, p < 0.001) for 2 or more complications compared to those without complications. In PCCS patients, 1 complication was associated with an HR of 2.22 (95% CI: 1.29, 3.81, p = 0.004) and 3.44 (95% CI: 2.04, 5.78, p < 0.001) for 2 or more complications. The most common complications in both non-PCCS and PCCS patients were bleeding (33% and 60%), need for RRT (31% and 43%), and severe hemolysis (26% and 35%). CONCLUSION: Complications among tMCS-treated patients are common and clearly associated with an elevated mortality risk.
引用
- Ott S, Germinario L, Müller-Wirtz LM, et al. Impact of complications on survival outcomes in different temporary mechanical circulatory support techniques: A large retrospective cohort study of cardiac surgical and nonsurgical patients. J Heart Lung Transplant. 2024. PMID: 39743051. doi:10.1016/j.healun.2024.12.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。